FDA Announces Clinical Trials Initiative
FDA has unveiled the Human Subject Protection and Bioresearch Monitoring Initiative, which aims to modernize the regulation of clinical trials and bioresearch monitoring in the device, drug, veterninary products, food, and biologics industries. This is part of the agency's Critical Path Initiative to get important health technologies to market more efficiently. Conducting clinical trials properly and choosing the right clinical endpoints have never been more important to the success of a device company.
The new initiative underscores that andÂ is something that must be paid attention to.